Navigation Links
Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
Date:4/1/2013

LA JOLLA, Calif., April 1, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has appointed William H. Rastetter , Ph.D. to its Board of Directors effective immediately. 

"We are extremely pleased to have Bill join our Board," said John Maraganore , Ph.D., Chairman of the Board of Directors of Regulus and CEO of Alnylam Pharmaceuticals, Inc. "Bill is an industry legend who has invented, developed and commercialized highly transformative therapies. He will be a valuable resource as we continue to grow the company and develop first-in-class medicines targeting microRNAs."

"Regulus' approach to treating complex, multi-factorial diseases by targeting microRNAs is very exciting," said Dr. Rastetter.  "I believe that Regulus' therapeutic platform has significant scientific and commercial potential and I look forward to collaborating with the Regulus team and Board of Directors to realize the power of microRNA therapeutics."

Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May 1996 to November 2003.  Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003, Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of 2005. From 2006 to 2013, Dr. Rastetter served as a partner in the venture capital firm, Venrock.  Dr. Rastetter currently serves as the Chairman of the Board of Directors of Fate Therapeutics, Inc., Illumina, Inc., Neurocrine Biosciences and Receptos, Inc.  He is the author of numerous scientific papers and patent applications in the fields of organic and bioorganic chemistry, protein and enzyme engineering, and biotechnology. Dr. Rastetter holds a S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
2. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
4. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
7. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus to Present at Two Upcoming Investor Conferences
10. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
11. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... The global ... expected to grow at a CAGR of 6.7% during 2016-2022 ... segment held the largest share in the global market in 2015. Among ...
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary  ... According to ... cannabis market research, the legal cannabis market is projected to ... despite conflicting signals from the current presidential administration. The report ... two biggest drivers of growth in this industry are the ...
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... The Radiology Business Management Association (RBMA) has ... now in their 12th year, are among the most prestigious in radiology marketing because ... awards were retooled to recognize achievements in both large budget (over $5,000) and small ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic ... Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru ... This sacred and spiritual journey during the Summer Solstice will also be ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the firm ... the firm, will concentrate her practice in elder law, Medicaid planning and applications, and ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true ... How to Walk with God #TruthwithGrace” is the creation of published author Lea ...
(Date:3/23/2017)... , ... March 23, 2017 , ... In 2016 the ... estimates that there could be four million Zika-related cases in the Americas within the ... numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, ...
Breaking Medicine News(10 mins):